A 503A pharmacy, also called a traditional compounding pharmacy, is a state-licensed pharmacy or physician that may compound GLP-1 drugs like semaglutide only for an individual patient with a prescription, and not as essentially a copy of a commercially available drug such as Ozempic or Wegovy. After FDA declared the semaglutide shortage resolved in February 2025, compounded options from these pharmacies became harder to get.Source
503B bulks list
The FDA's 503B bulks list names the bulk drug substances that outsourcing facilities may legally use to compound medications, and in April 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from it after finding no clinical need. For a US patient, this means compounded versions of drugs like Ozempic or Mounjaro would generally be off limits to outsourcing facilities unless the FDA-approved product is in shortage at the time.Source
503B outsourcing facility
Under section 503B of the FD&C Act, an outsourcing facility may compound GLP-1 drugs like semaglutide from bulk drug substances only if the substance appears on the FDA's 503B bulks list or the drug is on FDA's shortage list. Since semaglutide and tirzepatide appear on neither list, these facilities generally cannot keep making copies of Ozempic or Wegovy, and FDA's grace period ended May 22, 2025.Source
A
ACA Marketplace plan
A health plan bought on the government-run exchange created under the Affordable Care Act, an option for people without the employer-sponsored coverage that KFF's 2025 Employer Health Benefits Survey tracks across 154 million people under 65. For a patient seeking a GLP-1 drug like Wegovy, this kind of individual plan may cover weight-loss medications differently than a job-based plan, so checking drug benefits before filling a prescription matters.Source
Accelerated approval
The FDA used its accelerated approval pathway to approve Wegovy (semaglutide) for MASH, a serious liver disease, based on liver biopsy results rather than long-term outcomes. In practice, this lets a GLP-1 medication reach patients sooner, but the maker must submit follow-up data to confirm the drug actually reduces death, transplants, and other liver-related events.Source
Acquired hypothalamic obesity
A rare condition of rapid, ongoing weight gain caused by injury to or dysfunction of the hypothalamus, most often after tumors such as craniopharyngioma or their treatment. In March 2026 the FDA approved Rhythm Pharmaceuticals' IMCIVREE (setmelanotide) as the first therapy for it, an option for the roughly 10,000 affected US patients that works on the MC4R pathway rather than GLP-1 drugs like Ozempic or Wegovy.Source
Active ingredient
In the FDA-approved Ozempic injection, the active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, listed in the prescribing information alongside inactive excipients. For a US patient, this means Ozempic, Wegovy, and Rybelsus all contain the same working ingredient, so a serious hypersensitivity reaction to semaglutide rules out taking any of them.Source
Active, not recruiting
A recruitment status on ClinicalTrials.gov showing that a study like SURMOUNT-MMO (NCT05556512) is underway but has finished signing up new participants. For a US patient, this means the trial is no longer accepting volunteers, so contacting the study team about joining would not lead to enrollment.Source
Adverse benefit determination
Under 45 CFR 147.136, an adverse benefit determination is a plan or insurer's denial of a claim, defined in 29 CFR 2560.503-1, and it also includes any rescission of coverage under 45 CFR 147.128. For a patient whose GLP-1 prescription such as Ozempic or Wegovy is rejected, this denial notice is the formal decision that triggers the right to an internal appeal and, if that fails, an external review.Source
Adverse reaction
In the Ozempic (semaglutide) FDA prescribing information, an adverse reaction is any unwanted or harmful effect a patient experiences while taking the drug, with the most common ones reported in at least 5% of patients being nausea, vomiting, diarrhea, abdominal pain, and constipation. Patients in the US who suspect an adverse reaction can report it to Novo Nordisk at 1-888-693-6742 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Source
Affiliate disclosure
Under the FTC's 2024 final rule on consumer reviews and testimonials (16 CFR Part 465), anyone paid or otherwise compensated for promoting a product—such as a website reviewing GLP-1 drugs like Ozempic or Wegovy—must clearly disclose that connection. For a US patient researching weight-loss injections, this means a visible disclosure helps reveal whether a recommendation is motivated by money rather than honest experience.Source
Alternative funding program
An alternative funding program (AFP) is a strategy some employers use to cut costs for expensive drugs, such as Ozempic or Wegovy, by removing them from the plan's formulary as non-essential benefits. In practice, a patient may be told the drug is not covered and steered toward manufacturer or charity assistance, with any spending not counting toward the deductible or out-of-pocket maximum.Source
Amylin
A hormone-related target in weight-loss drug research, tested in the REDEFINE 1 trial through cagrilintide, an amylin-based medication given alongside semaglutide (the drug in Wegovy) as a combination called CagriSema. In that 68-week trial, the pairing produced an average body-weight reduction of 20.4%, so amylin-based treatments may become another option for US patients beyond GLP-1 medications alone.Source
ANDA
An abbreviated new drug application is the FDA filing a manufacturer submits to win approval for a generic version of a drug, such as the generic liraglutide injection referencing Victoza that the FDA approved in December 2024. The FDA prioritizes reviewing these applications for GLP-1 drugs in shortage, which can bring patients more affordable treatment options faster.Source
Anti-drug antibodies
Anti-drug antibodies are proteins the immune system can make in response to a medication such as Mounjaro (tirzepatide), though the Mounjaro prescribing information does not list them among its reported adverse reactions. In practice, a US patient would learn about any such immune response through their prescriber, since the label instead highlights hypersensitivity reactions like anaphylaxis and angioedema as the immune-related risks to watch for.Source
Anti-obesity medication
Anti-obesity medications, or AOMs, are drugs covered in the Obesity Association's Standards of Care in Overweight and Obesity, a guideline set that includes FDA-approved options such as semaglutide (Wegovy) and tirzepatide (Zepbound). For US patients, these guidelines mean doctors should offer medications as part of an initial treatment plan, with long-term management, nutrition monitoring, and shared decision-making.Source
API
The active pharmaceutical ingredient is the chemical that gives a GLP-1 drug its effect, such as semaglutide in Ozempic or Wegovy, and FDA Import Alert 66-80 covers foreign-made GLP-1 APIs shipped into the US for compounding. In practice, shipments can be detained at the border unless the maker is on the alert's Green List.Source
Apnea-hypopnea index (AHI)
In the SURMOUNT-OSA trials of tirzepatide (Mounjaro and Zepbound), the apnea-hypopnea index counted the number of breathing pauses and shallow-breathing episodes a person had during each hour of sleep, serving as the main measure of obstructive sleep apnea severity. After 52 weeks, tirzepatide lowered participants' AHI by roughly 25 to 29 events per hour, compared with about 5 for placebo, showing how much the drug reduced disordered breathing.Source
Area postrema
The source text does not mention the area postrema, so a definition cannot be written from it. The study it describes focused on GLP-1 receptor locations in the pancreas, kidney, lung, heart, and gastrointestinal tract of humans and monkeys, not this brain region.Source
Asynchronous prescribing
In the GLP-1 market, this refers to telehealth companies prescribing drugs like compounded semaglutide through online forms or questionnaires rather than a real-time visit with a clinician. The FDA has warned such companies against using this model to promote compounded GLP-1 drugs with false or misleading claims, since patients cannot make informed decisions based on inaccurate information.Source
Authorized generic
An authorized generic is a version of a brand-name drug sold under its generic name with the original maker's approval, as when Teva launched an authorized generic of Victoza (liraglutide injection 1.8 mg) in the United States in June 2024. For US patients, it can mean a lower-cost option for the same medicine, and this launch marked the first generic GLP-1 product available in the US marketplace.Source
B
Bariatric surgery
For patients with severe obesity, bariatric surgery is currently the most efficient treatment, producing durable weight loss, improved cardiovascular risk factors, and reduced all-cause mortality. A Swiss study found that when 16–37% of patients regain weight after the procedure, GLP-1 drugs like semaglutide and liraglutide can help them lose about two-thirds of that regained weight.Source
Bellwether trial
In MDL-3163, the federal litigation over NAION vision loss allegedly caused by Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound, a bellwether trial is a small test case chosen by Judge Karen S. Marston to go to trial before the rest. For a US patient with a pending claim, these early outcomes often shape settlement talks, though in this newly formed MDL, bellwether trials are likely years away.Source
Biased agonism
In the context of GLP-1 medications, biased agonism refers to how a drug like semaglutide activates the GLP-1 receptor in a way that favors one signaling pathway, since the receptor signals primarily through the stimulatory G protein Gs. The cryo-EM structure of the activated GLP-1R-Gs complex showed how hormone binding reshapes the receptor to engage Gs, giving researchers a framework for designing drugs that may steer signaling toward desired effects.Source
Bioavailability
For oral semaglutide tablets like Rybelsus, bioavailability refers to how much of the swallowed drug actually reaches the bloodstream, which is why the FDA label requires taking it on an empty stomach with no more than 4 ounces of water and waiting 30 minutes before food, drinks, or other oral medicines. Following these steps matters because food or other liquids can reduce how well the tablet absorbs.Source
Biosimilar
A biosimilar is a follow-on version of a biologic medicine, and regulators in countries like Brazil, India, and South Africa classify semaglutide, the active ingredient in Ozempic and Wegovy, this way—especially when it is made with recombinant technology. The FDA, however, treats semaglutide as a generic because its peptide chain is under 40 amino acids, which shapes how cheaper copies will be approved and priced in the US.Source
BMI
Body mass index, a measure that combines height and weight, is the standard the FDA uses to define obesity and overweight in the Wegovy (semaglutide) prescribing information. In practice, adults with a BMI in the obesity range, or in the overweight range plus at least one weight-related health condition, are the patients Wegovy is approved to treat for weight reduction.Source
Boxed warning
The FDA's strongest drug safety alert, which appears in a boxed section at the top of the Ozempic (semaglutide) prescribing information to warn about the risk of thyroid C-cell tumors. For patients, it signals that semaglutide caused these tumors in rodents, that human risk is unknown, and that anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use the drug.Source
Brand disambiguation
Mounjaro and Zepbound are two brand names for the same active ingredient, tirzepatide, sold by Eli Lilly, with Zepbound FDA-approved for weight loss and obstructive sleep apnea in adults with obesity. Knowing which brand a prescription refers to matters because the labeling, approved uses, and insurance coverage differ even though the drug itself is the same.Source
C
Cardiovascular outcomes trial
A cardiovascular outcomes trial, or CVOT, is a clinical study in human volunteers that measures whether a drug affects heart-related health outcomes, such as deaths from any cause, rather than just weight or blood sugar. For GLP-1 medications like semaglutide, the SELECT trial registered on ClinicalTrials.gov is this type of study, and its results help US patients and doctors understand the drug's effects on the heart beyond its approved uses.Source
Chronic weight management
The FDA has approved Wegovy (semaglutide) to reduce excess body weight and maintain that weight reduction long term in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related health condition. In practice, this means Wegovy is meant to be taken alongside a reduced-calorie diet and more exercise for ongoing use, not as a short-term fix.Source
Class action
The FTC's July 2025 case against NextMed over deceptive GLP-1 weight-loss advertising was an agency enforcement action, not a class action, and its December 2025 final order required $150,000 in payments for consumer refunds. For US patients, this means a government agency can pursue refunds and stop misleading practices tied to drugs like Wegovy and Ozempic without a group lawsuit.Source
Clinical obesity
A Lancet Diabetes & Endocrinology commission proposed this diagnosis in 2025 for obesity severe enough that excess body fat is harming how an organ or the whole body functions. For a US patient considering GLP-1 drugs like Wegovy or Zepbound, this label can signal a stronger medical reason for treatment than body weight or BMI alone.Source
Coinsurance
One of the cost-sharing provisions that employer health plans use, alongside premiums and deductibles, when covering prescription drugs such as GLP-1 agonists for weight loss, according to KFF's 2025 Employer Health Benefits Survey. For a US patient filling a drug like Wegovy, it means paying a set percentage of the covered cost rather than a flat fee, so the out-of-pocket amount rises with the drug's price.Source
Compounded dosing error
The FDA has reported dosing errors with compounded injectable semaglutide, where patients drew five to 20 times the intended dose from multiple-dose vials or providers miscalculated conversions between milligrams, milliliters, and "units." Some patients needed hospitalization for severe nausea, vomiting, low blood sugar, or pancreatitis, which is why the FDA urges anyone using compounded semaglutide to confirm the correct syringe size and dose with their provider or compounder.Source
Compounding
Pharmacies can make custom versions of GLP-1 drugs such as semaglutide and tirzepatide, a practice the FDA says may be appropriate only when an approved drug cannot meet a patient's medical need or is not commercially available. Because compounded GLP-1 drugs are not FDA approved, they are not reviewed for safety, effectiveness, or quality, so patients should use a doctor's prescription and a state-licensed pharmacy.Source
Conference abstract
A conference abstract is a short summary of clinical study results, such as those from the STEP 1 trial of semaglutide (Wegovy), presented at a scientific meeting before or instead of a full published paper. For a US patient, it offers an early look at findings on a GLP-1 medication, but the data are usually less complete and less fully reviewed than a final journal publication.Source
Contraindication
In the FDA prescribing information for Ozempic (semaglutide), a contraindication is a situation where the drug should not be used, such as a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or a serious hypersensitivity reaction to semaglutide. For a US patient, this means a doctor should not prescribe Ozempic if any of these apply, so sharing your full medical and family history matters before starting treatment.Source
Copay
Under the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 through December 31, 2027, eligible Part D beneficiaries pay a $50 copay for eligible GLP-1 drugs. Because these drugs are furnished outside the Part D benefit, the deductible does not apply, the $50 does not count toward TrOOP costs, and no low-income subsidy is available.Source
Copay accumulator
A copay accumulator, also called an accumulator adjustment program, is a commercial insurance strategy in which manufacturer copay support for a high-priced drug like Ozempic or Wegovy does not count toward the patient's deductible or out-of-pocket maximum. In practice, a patient using a manufacturer coupon may face the full cost once the coupon runs out, because those dollars never reduce the annual limit.Source
Copay card
A copay card, also called a savings card or savings offer, is a Novo Nordisk program that lets insured patients pay as little as $25 per month for Wegovy or Ozempic, with savings capped at $100 per month. It lowers out-of-pocket costs for commercially insured US patients, though government beneficiaries like Medicare are excluded and the offer can change or end at any time.Source
Copay maximizer
A copay maximizer is a program some commercial insurance plans use to shift more of the cost of high-priced drugs like Ozempic or Wegovy onto the drug manufacturer by counting manufacturer copay assistance toward a patient's deductible and out-of-pocket maximum. In practice, the copay card may stop lowering the monthly cost partway through the year, leaving the patient to pay the full price.Source
Counterfeit pen
A fake version of the Ozempic (semaglutide) injection pen that has repeatedly entered the legitimate U.S. drug supply chain, prompting FDA seizures and warnings in 2023 and 2025. Patients should check their pen's label — for example, authentic Ozempic shows the EXP/LOT text above the expiration date and lot number — and only buy through state-licensed pharmacies with a valid prescription.Source
D
Deductible
Under employer health plans tracked in KFF's 2025 Employer Health Benefits Survey, a deductible is the amount a covered worker must pay out of pocket each year before the plan starts sharing costs, averaging $1,886 for single coverage. For a patient filling a GLP-1 prescription like Wegovy or Ozempic, a higher deductible can mean paying the full price until that amount is met.Source
DEXA scan
A DEXA scan, or dual energy X-ray absorptiometry, was the tool used in the STEP 1 trial substudy to measure how semaglutide 2.4 mg changed participants' fat mass, lean body mass, and visceral fat over 68 weeks. For patients, it offers a way to see whether weight lost on a GLP-1 medication is coming more from fat than from muscle.Source
Diabetic retinopathy
Diabetic retinopathy complications were reported in a clinical trial of Ozempic (semaglutide), an FDA-approved GLP-1 injection for type 2 diabetes, and are listed as a warning in its prescribing information. In practice, patients with a history of diabetic retinopathy should be monitored by their healthcare provider while using Ozempic.Source
Dietary Supplement Health and Education Act
Under this 1990s-era law, the FDA does not review or approve over-the-counter dietary supplements for safety or efficacy, and it does not require certification of substance purity on labels, although all ingredients must be listed. For a US patient, this means weight loss supplements sold alongside GLP-1 medications like Ozempic or Wegovy carry no government vetting, and some have been found to contain illegal adulterants that pose serious safety risks.Source
Direct-to-consumer pharmacy
NovoCare Pharmacy, run by Novo Nordisk, is a direct-to-consumer pharmacy that sells FDA-approved Wegovy and Ozempic (semaglutide) with self-pay pricing from $149 to $199 per month or through insurance, with no insurance required. In practice, a US patient can get a prescription through telehealth, then choose free home delivery or pharmacy pickup, paying as little as $25 per month with insurance for up to three months.Source
Dose step-down
In the SURMOUNT-MAINTAIN trial, a dose step-down meant lowering tirzepatide from the maximum tolerated dose of 10 or 15 mg to a reduced 5 mg weekly dose during weight maintenance. Patients on the lower 5 mg dose still kept most of their weight loss, though somewhat less than those who stayed at the higher dose, giving US patients evidence about what to expect when reducing treatment intensity.Source
DPP-4
The enzyme that rapidly breaks down GLP-1, the gut hormone that Ozempic, Wegovy, and Rybelsus are designed to mimic, leaving it inactive in the body. Drugs called DPP-4 inhibitors work differently from semaglutide by protecting the body's own GLP-1 from this breakdown, which is why they appear as a separate older class of type 2 diabetes pills.Source
Drug shortage list
The FDA's drug shortage list is a public record of medications whose US demand exceeds supply, and it included the semaglutide injections Wegovy (added March 2022) and Ozempic (added August 2022) until FDA declared the shortage resolved on February 21, 2025. A drug's presence on this list allowed pharmacies to compound copies of it, so the removal of Ozempic and Wegovy set deadlines that ended most compounded semaglutide sales.Source
Dual GIP/GLP-1 receptor agonist
Mounjaro (tirzepatide) works as a dual GIP/GLP-1 receptor agonist, meaning the drug activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This two-target action is what separates tirzepatide from single-target GLP-1 drugs like Ozempic and Wegovy, and it is the basis for Mounjaro's FDA-approved use in type 2 diabetes and cardiovascular risk reduction.Source
Dulaglutide
The active ingredient in Trulicity, a once-weekly GLP-1 receptor agonist injection from Eli Lilly, FDA-approved in 2014 for type 2 diabetes and for lowering cardiovascular risk in adults with heart disease or risk factors. Unlike semaglutide products such as Ozempic and Wegovy, it comes in single-dose pens up to 4.5 mg, so patients comparing GLP-1 options may encounter it as an alternative with a different dosing schedule.Source
Dysesthesia
An adverse reaction reported by at least 5% of adults and pediatric patients aged 12 and older treated with Wegovy (semaglutide) in clinical trials, according to FDA prescribing information. A US patient taking Wegovy who notices this kind of uncomfortable or unusual sensation should mention it to a healthcare provider.Source
E
"Essentially a copy"
Under FDA guidance for section 503A of the FD&C Act, a compounded GLP-1 drug is essentially a copy of a product like Ozempic or Wegovy when it has the same active ingredient in a similar strength and is given the same way, such as by injection. Since FDA declared the semaglutide shortage resolved, pharmacies cannot regularly compound these copies unless a prescriber documents a significant difference for a patient.Source
Efficacy supplement
An efficacy supplement is a request a drugmaker files with the FDA to update an approved drug's label based on new clinical evidence, as Eli Lilly did for Mounjaro (tirzepatide) using results from pediatric trial I8F-MC-GPGV. When the FDA approves one, the official prescribing information changes, which for US patients can mean expanded approved uses, such as Mounjaro becoming available for children aged 10 and older with type 2 diabetes.Source
eGFR
A lab value that estimates how well the kidneys filter blood, used in the Ozempic kidney outcomes trial and named in the FDA-approved indication for adults with type 2 diabetes and chronic kidney disease. The FDA label states that Ozempic reduces the risk of sustained eGFR decline, so doctors may track this number during treatment.Source
ERISA class action
The source text does not mention any ERISA class action. It covers CVS Caremark's decision to restore Zepbound (tirzepatide) to its commercial formularies effective Oct. 1, 2026, and to lift the new-to-market block on Foundayo (orforglipron) effective June 1, 2026. Because the term does not appear in the source material, no GLP-1-specific definition can be provided.Source
Estimand
In the STEP 1 trial record on ClinicalTrials.gov, the estimand is the precise question a trial analysis is designed to answer, spelling out the treatment, the population, the outcome being measured, and how data from participants who stop taking semaglutide or leave the trial are handled. For a US patient reading Wegovy study results, it explains exactly what the reported weight-loss numbers represent and under what conditions they were measured.Source
Estimated primary completion date
On ClinicalTrials.gov, this is the projected date when a trial such as SURMOUNT-MMO (NCT05556512) expects to finish collecting data for its primary outcome, the main measurement the study was designed to answer. For a US patient, it offers a rough sense of when key results might be available, though sponsors can revise the date and results are often posted later.Source
European Public Assessment Report (EPAR)
The European Public Assessment Report is the European Medicines Agency's published scientific review of Mounjaro (tirzepatide), which led the European Commission to grant marketing authorisation across the EU on 15 September 2022. For a US patient, it offers a free, official summary of the same drug's studied benefits, side effects, and dosing, useful for comparing how regulators outside the FDA view the medication.Source
Exclusivity
A period of protection that lets a brand-name drug maker, such as Novo Nordisk with Ozempic, keep generic competitors off the market. When it ends, regulators can authorize cheaper copies, as Health Canada did in April 2026 with Dr. Reddy's generic semaglutide, the first approved in the G7.Source
Exenatide
Sold as Byetta, Bydureon, and Bydureon BCise, this GLP-1 receptor agonist was FDA-approved to improve blood sugar control in people with type 2 diabetes, including children aged 10 and older for the extended-release forms. An April 2025 FDA pediatric safety review found no new safety concerns, but all three products have been discontinued from the U.S. market, leaving patients to rely on other GLP-1 options like semaglutide.Source
External review
When a plan denies coverage for a GLP-1 medication like Ozempic or Wegovy and an internal appeal fails, an external review lets an independent reviewer outside the insurer reconsider the denial. The reviewer's decision is legally binding on the insurer, so a patient whose semaglutide claim was rejected as not medically necessary can win coverage this way.Source
F
FAERS / AEMS
The FDA's Adverse Event Monitoring System (AEMS) is a new unified platform that will replace the older FAERS database for collecting adverse event, medication error, and product quality reports on drugs like Ozempic, Wegovy, and Rybelsus. For US patients, side effects and problems with GLP-1 medications reported here feed the FDA's post-marketing safety surveillance, helping the agency spot trends and make timely regulatory decisions.Source
Fibrosis
In the FDA's 2025 approval of Wegovy for MASH, fibrosis refers to excessive scar tissue that builds up in the liver, ranging from moderate to advanced stages. The approval matters because trial results showed 37% of Wegovy patients had improvement in liver scarring without MASH worsening, versus 22% on placebo.Source
Flexible spending account
Under IRS Publication 502, a flexible spending account (FSA) is an employer-sponsored account that lets a worker set aside pre-tax dollars to pay for qualified medical expenses, which include prescription medicines such as Ozempic, Wegovy, and Rybelsus. For a US patient filling a GLP-1 prescription, FSA funds can lower the out-of-pocket cost because the money is never taxed, though the account typically must be spent within the plan year.Source
Food noise
Food noise describes persistent, unwanted thoughts about food—what to eat, calories, or meal timing—that feel intrusive and unpleasant, and researchers are still developing a formal definition and measurement tools such as the RAID-FN Inventory. Patients on GLP-1 medications like Ozempic or Wegovy often report this mental chatter quiets down, which may explain why constant food preoccupation has been cited as a reason weight-loss attempts fail.Source
Form 10-K
Eli Lilly and Company, the maker of Mounjaro and Zepbound, files this annual report with the US Securities and Exchange Commission to detail its finances, product sales, patents, and business risks for each fiscal year. For a US patient, it is a public source showing how much revenue drugs like Mounjaro and Zepbound generate, which can signal how much the company invests in supply and future GLP-1 treatments.Source
Formulary
Under employer-sponsored health plans, the drugs a plan chooses to cover—such as GLP-1 agonists like Wegovy for weight loss—are determined by the employer and insurer, as KFF's 2025 Employer Health Benefits Survey shows in its questions about GLP-1 coverage. For a US patient, whether a GLP-1 medication is covered can decide whether they pay a small copay or the full price out of pocket.Source
Formulary exception
A formulary exception, also called a coverage exception, is a request a Medicare Part D enrollee, prescriber, or representative can make to get a drug the plan's formulary does not cover, or to waive a rule like step therapy or a quantity limit. For a patient seeking a GLP-1 medication, the prescriber must submit a supporting statement, and the plan must respond within 72 hours for standard requests.Source
Formulary exclusion
A formulary exclusion happens when an insurer or employer plan leaves a drug, such as Wegovy or Zepbound, off its list of covered medications, a practice KFF's 2025 Employer Health Benefits Survey examined through questions on GLP-1 coverage for weight loss. For a US patient, the plan will not pay for the drug, so the full price falls on the patient unless the employer adds coverage.Source
Foundayo
Orforglipron, sold under the brand name Foundayo, is a once-daily GLP-1 tablet made by Eli Lilly that the FDA approved in 2026 for weight loss in adults with obesity or overweight plus a weight-related condition. Unlike injected drugs such as Ozempic or Wegovy, it comes as a pill taken with or without food, starting at 0.8 mg and stepping up over months to a maximum of 17.2 mg daily.Source
G
Gastric emptying
Ozempic (semaglutide) delays gastric emptying, the process by which food leaves the stomach and moves into the intestine, according to the FDA prescribing information. In practice, this can affect how the body absorbs oral medications taken along with Ozempic, so patients should use other oral drugs with caution and discuss timing with their healthcare provider.Source
Gastroparesis
Severe, persistent nausea and vomiting during treatment with GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) have been described in reports as a form of stomach paralysis, in which the stomach empties much more slowly than normal. For a US patient, this matters because the expert consensus stresses telling a healthcare provider about GI symptoms during dose increases so the dose can be adjusted rather than stopping treatment abruptly.Source
Generic drug
A copy of a brand-name GLP-1 medication that the FDA has reviewed and approved as safe and effective, such as the generic liraglutide injection referencing Victoza that the FDA approved in December 2024. For US patients, generics usually cost less than the brand-name drug and give more treatment options, which is why the FDA prioritizes them when GLP-1 medications are in shortage.Source
GIP
GIP, or glucose-dependent insulinotropic polypeptide, is a gut hormone whose receptor tirzepatide (Mounjaro) activates alongside the GLP-1 receptor, per the FDA-approved prescribing information. This dual action is what sets Mounjaro apart from GLP-1-only drugs like Ozempic or Wegovy for US patients managing type 2 diabetes.Source
GIP receptor (GIPR)
A cell-surface protein that tirzepatide (Mounjaro and Zepbound) attaches to and activates, alongside the GLP-1 receptor, making it a dual-action medication. This dual receptor activity is what separates tirzepatide from single-target GLP-1 drugs like semaglutide (Ozempic, Wegovy, and Rybelsus).Source
GLP-1
GLP-1, short for glucagon-like peptide-1, is a gut hormone that stimulates insulin secretion after meals, and it is the hormone from which diabetes drugs like Ozempic and Rybelsus (semaglutide) were developed. In practice, it explains why these medications help control blood sugar in US patients with type 2 diabetes.Source
GLP-1 booster
Sold over the counter as "natural" alternatives to drugs like Ozempic and Wegovy, these supplements typically contain berberine, chromium, fiber, green tea extract, or probiotics, and they do not activate GLP-1 receptors the way prescription medications do. The FDA has warned that some weight-loss supplements contain hidden drug ingredients, so a US patient should not treat them as substitutes for FDA-approved GLP-1 drugs.Source
GLP-1 microdosing
Taking GLP-1 medications at doses smaller than those studied and approved by the FDA, often through compounded semaglutide or tirzepatide sold by telehealth companies or compounders rather than approved products like Ozempic or Wegovy. The FDA has received adverse event reports tied to compounded semaglutide and tirzepatide dosed outside the approved label, so patients should ask a licensed doctor how to measure and take the intended dose.Source
GLP-1 receptor agonist
Ozempic (semaglutide), approved by the FDA in 2017, belongs to a drug class called glucagon-like peptide 1 (GLP-1) receptor agonists, used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. For a US patient, this class name is what doctors, pharmacists, and insurance paperwork use when describing how Ozempic and similar medications work.Source
Glucose-dependent
In Ozempic (semaglutide), the FDA-approved GLP-1 receptor agonist, insulin release that lowers blood sugar occurs only when the body needs it, supporting glycemic control in adults with type 2 diabetes. For a US patient, this lowers the risk of hypoglycemia from Ozempic alone, though combining it with insulin or an insulin secretagogue can still raise that risk.Source
Gold carding
A prior authorization exemption used by insurers such as Highmark Health, gold carding removes approval requirements for providers who meet a high standard of adherence to evidence-based care guidelines. For a patient seeking a GLP-1 prescription, a gold-carded doctor can get near-instant approval without submitting clinical information, cutting delays between diagnosis and treatment.Source
H
Half-life
Semaglutide, the active ingredient in Ozempic, stays in the body long enough that the FDA-approved label calls for dosing just once weekly, with a missed dose allowed up to 5 days late. In practice, this long half-life means the drug builds up steadily and clears slowly, which is also why the label advises stopping Ozempic at least 2 months before a planned pregnancy.Source
HbA1c
A blood test that measures average blood sugar over time, used in FDA-approved Ozempic labeling as the main measure of glycemic control in adults with type 2 diabetes. In practice, doctors use HbA1c results to decide whether an Ozempic dose should stay the same or be raised, since the label allows increases from 0.5 mg up to a maximum of 2 mg weekly when more glycemic control is needed.Source
Health savings account
A health savings account (HSA) is a tax-advantaged account the IRS allows to be used for qualified medical and dental expenses, which under IRS Publication 502 include prescription medicines and drugs. For a US patient paying for a GLP-1 medication such as Ozempic or Wegovy, HSA funds can cover the cost of a prescribed drug, which matters because these medicines are often expensive and insurance coverage varies.Source
HFpEF
HFpEF, or heart failure with preserved ejection fraction, is a form of heart failure that accounts for more than half of all US heart failure cases and is especially common in people with obesity. In the STEP-HFpEF trial, semaglutide 2.4 mg reduced symptoms, improved walking distance, and produced about 13% weight loss over 52 weeks.Source
Hypoglycemia
In the Ozempic (semaglutide) FDA prescribing information, hypoglycemia, or low blood sugar, is a warning tied to taking Ozempic together with insulin or an insulin secretagogue such as a sulfonylurea, which can raise the risk of severe hypoglycemia. In practice, a patient using these drugs with Ozempic may need the insulin or secretagogue dose lowered, so this should be discussed with a healthcare provider.Source
I
Ileus
A serious digestive complication in which the intestines stop moving contents forward, ileus falls under the severe gastrointestinal adverse reactions that the FDA's Ozempic (semaglutide) label warns about. Because Ozempic slows stomach emptying and is not recommended in patients with severe gastroparesis, a patient taking it who develops signs of a blocked or inactive gut should contact a healthcare provider right away.Source
Import Alert
An import alert is an enforcement tool the FDA can use to keep tirzepatide-containing products, such as unapproved versions of Mounjaro or Zepbound, from entering the United States at the border. For a US patient, it signals that the agency has flagged those products as risky or unapproved, so buying them from overseas sellers carries legal and safety concerns.Source
In-use storage window
For Ozempic (semaglutide), the in-use storage window is the period after a single-patient-use pen is first used, during which its remaining weekly doses can still be injected. In practice, a US patient keeps using the same pen for the following weeks of once-weekly doses, and the pen must never be shared with another person, even with a new needle.Source
Incretin
Incretins are gut hormones released during digestion that stimulate insulin secretion at normal body levels, with GLP-1 and GIP being the two best-known examples. Semaglutide drugs like Ozempic, Wegovy and Rybelsus copy the action of the GLP-1 incretin, which is why they help control blood sugar after meals.Source
Incretin effect
The incretin effect describes how gut hormones released during digestion, mainly GLP-1 and GIP, stimulate insulin release at natural, meal-related levels in the body. It explains why drugs like Ozempic and Wegovy, which copy GLP-1, can help control blood sugar after eating in people with type 2 diabetes.Source
Incretin market share
In the GLP-1 market, incretin market share describes how sales and prescriptions are divided among incretin-based drugs, led by Novo Nordisk's semaglutide brands Ozempic and Wegovy and Lilly's tirzepatide brands Mounjaro and Zepbound. For US patients, this competition among manufacturers shapes advertising, availability, and pricing as the drug class grows toward billions in monthly sales.Source
Indication
In the FDA-approved labeling for Ozempic, an indication is the specific health condition the agency has cleared the drug to treat, such as improving blood sugar control in adults with type 2 diabetes or reducing the risk of major cardiovascular events. For a US patient, this means insurance coverage and prescribing typically line up with these approved uses, so a doctor may need to justify any use outside them.Source
Internal appeal
An internal appeal, or first-level appeal, is the first step under ERISA rules (29 CFR 2560.503-1) for asking a group health plan to reconsider a denied claim, such as coverage for a GLP-1 drug like Ozempic or Wegovy. In practice, the plan must review the appeal under federal procedural requirements, giving the patient a required path to challenge a denial before further action.Source
International price gap
Peterson-KFF analysis found that list prices for semaglutide drugs like Ozempic, Wegovy, and Rybelsus, plus tirzepatide (Mounjaro), run far higher in the U.S. than in other wealthy nations—for example, a month of Ozempic costs $936 in the U.S. versus $169 in Japan and $87 in Australia. For a US patient, this gap means paying several times more before insurance, though coupons and insurer rebates can lower the real out-of-pocket cost.Source
K
KwikPen
A KwikPen is the single-patient, multi-dose injector format of Zepbound, Eli Lilly's tirzepatide medicine for obesity and obstructive sleep apnea, available in doses from 2.5 mg up to 15 mg. For US patients paying out of pocket, the Zepbound KwikPen carries self-pay pricing starting at $299 a month at major pharmacies and through LillyDirect, and it should never be shared with another person.Source
L
Label / prescribing information
The FDA-approved prescribing information for Ozempic, published by Novo Nordisk on DailyMed, spells out the drug's approved uses, dosing steps, warnings, and side effects. Patients can read the free consumer version online to check exactly how semaglutide is supposed to be taken and which risks, like the boxed thyroid tumor warning, the FDA requires to be disclosed.Source
Lanham Act claim
A Lanham Act claim, as used here, is the false-advertising lawsuit Novo Nordisk filed against Eli Lilly in federal court in New Jersey over ads for Zepbound and Mounjaro that compared Lilly's highest doses against lower doses of Wegovy and Ozempic. For US patients, it matters because Novo Nordisk wants the ads pulled and corrected, so people comparing GLP-1 medicines see complete, current evidence.Source
Lean mass
In the STEP 1 trial of semaglutide 2.4 mg (Wegovy), adults with overweight or obesity lost about 9.7% of their total lean body mass, the tissue that includes muscle, over 68 weeks. Because fat fell even faster than lean mass, the lean-to-fat ratio actually improved, meaning patients lost proportionally more fat than muscle even though some muscle loss occurred.Source
Letter of medical necessity
A letter of medical necessity (LOMN) is a document a prescriber sends to a patient's prescription drug plan to justify coverage of a weight-loss medication, citing the patient's diagnosis, BMI, weight-related comorbidities, and prior treatments that failed. For a US patient, this letter and its matching medical necessity form can be the key to getting a plan to approve and reimburse the prescription.Source
LillyDirect
Eli Lilly's direct-to-patient website and pharmacy, LillyDirect fills prescriptions of Zepbound (tirzepatide) in KwikPen, single-dose vial, and single-dose pen forms with free delivery or pickup. For US patients, self-pay prices start at $299 a month for the 2.5 mg starting dose, savings are applied automatically, and eligible Medicare Part D patients can reach Zepbound through the Medicare GLP-1 Bridge program.Source
Lipase inhibitor
Lipase inhibitors are a separate class of weight-loss drugs, sold as orlistat under the names Alli (over-the-counter) and Xenical (prescription), that block lipase, the enzyme that breaks down dietary fat in the intestine. Unlike GLP-1 medications such as Ozempic or Wegovy, orlistat cuts fat absorption by up to 30% at the 120 mg dose, which is why oily stools and other gastrointestinal side effects are common.Source
Liraglutide
The active ingredient in Saxenda, a GLP-1 receptor agonist injection made by Novo Nordisk that the FDA first approved in 2010 for weight management alongside diet and exercise. Unlike Ozempic or Wegovy, it is injected once daily at a target dose of 3 mg, and its label warns against combining it with any other GLP-1 medication.Source
M
MACE
Major adverse cardiovascular events, or MACE, is a term the FDA uses for the combined outcomes of cardiovascular death, non-fatal heart attack, and non-fatal stroke. Wegovy is FDA-approved to reduce the risk of these events in adults with established cardiovascular disease who also have obesity or overweight, which is why it may be prescribed for heart protection, not just weight loss.Source
Maintenance dose
For Wegovy (semaglutide), the maintenance dose is the steady amount reached after gradually stepping up from a low starting dose, typically 2.4 mg once weekly for the injection or 25 mg once daily for the tablets. A US patient works up to this target through dose increases every 4 weeks (injection) or every 30 days (tablets), then stays on it long term.Source
MASH
A serious liver disease, formerly called NASH, in which fat buildup causes inflammation and scarring; the FDA approved Wegovy (semaglutide) in 2025 to treat it in adults with moderate-to-advanced liver fibrosis. About 6% of US adults have MASH, and many have no symptoms until severe damage occurs, so this approval gives patients a medication option alongside diet and lifestyle changes.Source
Maximum fair price
Under the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, CMS negotiated a maximum fair price for Ozempic, Rybelsus, and Wegovy, with the new price taking effect January 1, 2027. For Medicare patients, this sets a lower negotiated price for a 30-day supply of these semaglutide drugs, and CMS publishes an explanation of how that price was reached.Source
MC4R agonist
An MC4R agonist is a drug that activates the melanocortin-4 receptor pathway, which regulates hunger, energy expenditure, and body weight; setmelanotide (IMCIVREE), made by Rhythm Pharmaceuticals, is the FDA-approved example for rare obesity conditions like acquired hypothalamic obesity. Unlike GLP-1 medications such as Ozempic or Wegovy, it targets a different biological pathway and is not indicated for general obesity, so most US patients using GLP-1 drugs would not take it.Source
MDL
The source text does not mention multidistrict litigation (MDL), so no definition can be written from it. The case described, Outsourcing Facilities Association v. FDA, was a single appeal in the Fifth Circuit, not an MDL proceeding.Source
Mediation analysis
The source text for the tirzepatide (Mounjaro/Zepbound) obstructive sleep apnea trials does not mention mediation analysis, so no definition can be written from it.Source
Medicaid
Under a long-standing statutory exception, state Medicaid programs can choose whether to cover GLP-1 weight-loss drugs like Wegovy for obesity, while coverage for diabetes, cardiovascular disease, and sleep apnea is required. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service, so access to drugs like Ozempic or Zepbound for weight loss depends heavily on which state a patient lives in.Source
Medical expense deduction
Under section 213 of the Internal Revenue Code, the IRS allows a federal income tax deduction for prescribed drugs like Ozempic or Wegovy when they treat a specific disease, such as obesity or diabetes. A patient paying out of pocket for a GLP-1 medication may deduct that cost, but not if it was already paid or reimbursed through an HSA, FSA, Archer MSA, or HRA.Source
Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026, through December 31, 2027. It works outside the normal Part D payment system, so eligible patients pay a flat $50 copay with no deductible, though that copay does not count toward out-of-pocket limits and low-income subsidy does not apply.Source
Medicare Part D
Optional prescription drug coverage from Medicare-approved private plans, Part D is what a person with Medicare needs to access GLP-1 drugs like Wegovy, Zepbound, and Foundayo through the Medicare GLP-1 Bridge program starting July 1, 2026. In practice, patients with a standalone drug plan or a Medicare Advantage plan with drug coverage may qualify, though anyone already getting GLP-1s paid for by Part D cannot join the Bridge.Source
Medicare Prescription Payment Plan
The Medicare Prescription Payment Plan (M3P) is a CMS program, running since 2025, that lets Medicare Part D enrollees spread out-of-pocket drug costs for medications like Ozempic or Wegovy into capped monthly payments instead of paying the full amount at the pharmacy. For a US patient on a GLP-1 with a high upfront copay, opting in can make an expensive prescription more manageable across the year.Source
Meta-analysis
A research method that combines the results of several separate studies into one pooled analysis, used here to merge four randomized controlled trials of GLP-1 receptor agonists against placebo in adults with obstructive sleep apnea. For a US patient, this pooled evidence showed the drugs cut apnea episodes by about 14 per hour, produced roughly 12 kg of weight loss, and lowered blood pressure.Source
Missed dose rule
For Ozempic (semaglutide), the FDA labeling says a missed weekly dose should be injected as soon as possible within 5 days, and if more than 5 days have passed, the missed dose should be skipped and the next one taken on the regularly scheduled day. This lets a patient get back on track without doubling up, then resume the normal once-weekly schedule.Source
Most-favored-nation pricing
Under a most-favored-nation (MFN) pricing policy announced by President Trump in 2025, drug makers like Novo Nordisk and Eli Lilly agreed to charge Americans no more than the lowest prices paid in other developed nations. For GLP-1 buyers, that drops Ozempic and Wegovy to $350 a month and Zepbound to about $346 through TrumpRx, with Medicare prices of $245 and a $50 monthly copay.Source
Mounjaro
Eli Lilly's brand name for tirzepatide, a once-weekly injection approved by the FDA in 2022 that acts on both GIP and GLP-1 receptors to improve blood sugar control in people with type 2 diabetes. A US patient typically starts at 2.5 mg weekly and can step up in 2.5 mg increments to a maximum of 15 mg, taken any time of day with or without meals.Source
Multi-dose pen
Ozempic comes in single-patient-use pens that hold multiple weekly doses, such as a 2 mg/3 mL pen delivering four 0.25 mg or two 0.5 mg doses. For a US patient, one pen can cover several weeks of once-weekly injections, and FDA labeling warns never to share a pen between patients, even if the needle is changed.Source
Multi-dose vial
A multi-dose vial is one of the ways Zepbound (tirzepatide) is supplied, containing 2.4 mL of liquid that holds four separate weekly doses, ranging from 10 mg/2.4 mL for four 2.5 mg doses up to 60 mg/2.4 mL for four 15 mg doses. For a patient, this packaging can cover a month of injections from a single vial instead of using a separate single-dose pen or vial each week.Source
N
NAION
An eye condition that may cause loss of vision, which EMA's safety committee (PRAC) concluded in June 2025 is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, affecting up to 1 in 10,000 people. Patients who notice sudden vision loss or rapidly worsening eyesight while taking semaglutide should contact a doctor without delay, and treatment should stop if NAION is confirmed.Source
National Drug Code
The National Drug Code (NDC) is a unique 10-digit, three-segment number the FDA assigns to listed drugs, including GLP-1 products like Ozempic, Wegovy, and Rybelsus, identifying the labeler, the strength and dosage form, and the package size. In practice, it appears on pharmacy labels and insurance claims, though inclusion in the FDA's NDC Directory does not by itself mean a product is FDA-approved or covered by Medicare or Medicaid.Source
National priority voucher
The FDA's Commissioner's National Priority Voucher (CNPV) pilot program, announced in June 2025, speeds up review of drug applications tied to national health priorities, targeting 1-2 months instead of the usual 6 or more. A higher-dose form of semaglutide was approved under this program on March 19, 2026, so GLP-1 products can reach US patients faster while still meeting the FDA's normal safety standards.Source
Nature's Ozempic
"Nature's Ozempic" is a marketing nickname for berberine, a plant chemical sold as a dietary supplement, based on social media claims that it helps with weight loss the same way Ozempic (semaglutide) does. The evidence does not support these claims, and any small reported weight reductions disappear when low-quality studies are excluded, so US consumers should treat the hype as exaggerated.Source
NCT number
ClinicalTrials.gov gives every registered study a unique code, formatted as "NCT" followed by eight digits, such as the STEP 1 trial record for semaglutide (Wegovy). A patient can search this number on the ClinicalTrials.gov website to pull up the full record for that specific GLP-1 study, including its results and enrollment details.Source
NDA
A new drug application, or NDA, is the filing a company submits to the FDA to request approval of a new prescription drug, such as Novo Nordisk's NDA 209637 for Ozempic. Once the FDA reviews the data in an NDA and approves it, the medication can legally be marketed in the United States.Source
NDC number
Every Ozempic product from Novo Nordisk carries a National Drug Code, a unique identifier such as 0169-4132-11 listed on the drug's outer packaging and on the FDA's DailyMed label. A patient can use this number to confirm exactly which Ozempic strength and package type a pharmacy has supplied, since different codes match different doses and pen or prefilled syringe sizes.Source
Net price
For GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, the net price is the amount actually paid after manufacturers subtract insurer rebates and patient coupons from the list price, per the Peterson-KFF drug price comparison. In practice, a U.S. patient's real cost can be much lower than the list price—for example, Wegovy coupons of $225 or $500 per 28-day supply, plus negotiated insurer discounts.Source
Non-inferiority
A non-inferiority trial is a type of clinical trial design, seen in records like the STEP 1 registry entry on ClinicalTrials.gov, that tests whether a new treatment such as semaglutide is not meaningfully worse than an existing treatment rather than better. For a US patient, this matters because a drug shown to be non-inferior may offer a simpler option, such as a pill instead of an injection, with similar effectiveness.Source
Notice of Compliance
A Notice of Compliance (NOC) is the formal approval a regulator issues when it decides a medicine's benefits outweigh its risks, similar to the marketing authorisation the European Medicines Agency granted for Mounjaro (tirzepatide) on 15 September 2022. For a US patient, it signals that an independent agency has reviewed the clinical evidence and judged the drug safe and effective enough to be sold with a prescription.Source
O
"Ozempic babies"
An informal phrase describing unplanned pregnancies that happen while a woman is taking Ozempic (semaglutide), a GLP-1 medication not licensed for use during pregnancy. Because semaglutide use among young women in the United States grew sharply between 2020 and 2023, more pregnancies are being exposed to the drug, and early case reports so far suggest no harm to the fetus.Source
"Ozempic face"
A phrase used to describe the exaggerated facial volume loss and aged appearance some people experience after losing weight rapidly on semaglutide drugs like Ozempic. A 2025 systematic review in Aesthetic Surgery Journal Open Forum found that rising searches for this term tracked with increased interest in facial fillers and plastic surgeons, so patients concerned about these changes often explore cosmetic procedures.Source
Obesity as a chronic disease
The FDA describes obesity and overweight as serious health issues affecting about 70% of American adults, raising the risk of early death, heart attack, and stroke. This framing supports treating obesity as a long-term medical condition, which is why Wegovy was approved for ongoing use alongside diet and exercise rather than as a short-term fix.Source
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is a condition in which the upper airway becomes blocked during sleep, causing pauses in breathing; in December 2024 the FDA approved Zepbound (tirzepatide) as the first medication to treat moderate to severe OSA in adults with obesity. For US patients, this means a GLP-1-based drug taken weekly alongside diet and exercise can reduce breathing pauses, largely through weight loss.Source
Off-label use
The FDA-approved label for Ozempic (semaglutide) lists its uses as improving blood sugar control in adults with type 2 diabetes, reducing major cardiovascular events in those with established cardiovascular disease, and reducing kidney-related decline and cardiovascular death in those with chronic kidney disease. Prescribing Ozempic for anything outside those listed uses, such as weight loss alone, would be off-label, meaning the FDA has not reviewed it for that purpose.Source
Oral contraceptive interaction
Mounjaro (tirzepatide) delays stomach emptying, which can reduce how much of an oral contraceptive pill the body absorbs. Because of this, the FDA label advises women using birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.Source
Orange Book
The FDA's Orange Book lists the patents and exclusivity periods attached to approved drugs, and the entry for Zepbound (tirzepatide, NDA 217806) shows patents on the drug, its autoinjector, and its dosing methods running as far out as 2039. For US patients, these listings signal how long cheaper generic versions of Zepbound may be blocked.Source
Orforglipron
Orforglipron, sold by Eli Lilly as Foundayo, is a GLP-1 receptor agonist in tablet form that the FDA approved in 2026 for weight management in adults with obesity or overweight plus a weight-related condition. Unlike injected semaglutides such as Ozempic and Wegovy, it is taken as a once-daily pill, with dosing that starts at 0.8 mg and can step up to a maximum of 17.2 mg.Source
Out-of-pocket cap
A limit on what a patient pays for a drug in a period, tied here to the maximum fair prices CMS negotiated with the manufacturer of Ozempic, Rybelsus, and Wegovy under the Medicare Drug Price Negotiation Program, effective January 1, 2027. For Medicare patients, the negotiated price for a 30-day supply of these semaglutide drugs can lower costs before any cap applies.Source
Ozempic
Novo Nordisk's FDA-approved brand of semaglutide, a once-weekly GLP-1 injection first approved in 2017 to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of cardiovascular events and kidney disease progression. US patients inject it under the skin of the abdomen, thigh, or upper arm, starting at 0.25 mg weekly and stepping up to a maximum of 2 mg.Source
Ozempic tablets
Ozempic tablets are an oral form of the GLP-1 receptor agonist semaglutide, covered with Rybelsus in FDA prescribing information for treating type 2 diabetes in adults. Patients swallow a tablet once daily on an empty stomach with water and wait at least 30 minutes before eating, drinking, or taking other oral medications.Source
P
Pancreatitis
Acute pancreatitis, a sudden inflammation of the pancreas, has been observed in patients treated with GLP-1 receptor agonists, including Ozempic (semaglutide), according to the FDA prescribing information. In practice, patients taking Ozempic should stop the drug and contact a healthcare provider right away if pancreatitis is suspected, since the label directs doctors to discontinue the medication in that situation.Source
Patent cliff
A patent cliff occurs when a brand-name drug like Ozempic loses its market exclusivity and generic competitors, such as the semaglutide injection from Dr. Reddy's Laboratories approved by Health Canada, enter the market. For patients, this shift can bring large price drops, since generic medications in Canada often cost 45 to 90% less than the brand-name versions.Source
Patient assistance program
Novo Nordisk runs NovoCare Pharmacy, a direct-to-patient program offering Wegovy and Ozempic at set self-pay prices, like $149 per month for the pills, with no insurance required. For a US patient, this can sharply cut the cost of semaglutide, though eligibility rules apply and Novo Nordisk can change or cancel the program at any time.Source
PBM
The KFF 2025 Employer Health Benefits Survey does not discuss pharmacy benefit managers, so no GLP-1-specific definition can be drawn from this source. A different source covering how PBMs negotiate drug prices or set coverage rules for medications like Ozempic or Wegovy would be needed.Source
PDUFA date
A PDUFA date is the FDA's target deadline for finishing a drug review, set under the user-fee agreements that fund those reviews. For GLP-1 medications, it signals when US patients can expect an approval decision, though programs like the National Priority Voucher that approved higher-dose semaglutide can move that decision up to months earlier.Source
Pediatric indication
A pediatric indication is FDA approval for a GLP-1 medication to be used in children, such as the 2025 expansion of Mounjaro (tirzepatide) to cover patients aged 10 and older with type 2 diabetes, based on the phase 3 GPGV trial. For a US patient, it means a doctor can now legally prescribe the drug to a child in that age group, since earlier approval covered only adults.Source
Peer-to-peer review
In the context of GLP-1 medications like Ozempic or Wegovy, a peer-to-peer review is a step in the insurer's appeals process where the prescribing provider speaks directly with the insurer's clinical reviewer after an adverse determination. For a patient whose semaglutide prior authorization was denied, this doctor-to-reviewer conversation can resolve the denial before a formal internal or external appeal.Source
Pen needle
A pen needle is the very fine, single-use needle that attaches to an injection pen, and it must be long enough to pass through the skin into the fat layer without reaching muscle. For GLP-1 pens such as Ozempic and Wegovy, FITTER workshop recommendations favor the shortest needles available, since injecting too deep can make the medication absorb unpredictably.Source
Peptide
Semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, is a peptide: a chain of 31 amino acids joined by peptide linkages, with a fatty acid attached that makes it longer-lasting in the body. For patients, this peptide structure is why the injection form works with a once-weekly dose while the tablet is taken once a day.Source
Perioperative guidance
The 2024 multi-society clinical practice guide, backed by groups like the American Gastroenterological Association and the American Society of Anesthesiologists, sets unified rules for safely managing patients on GLP-1 medications like Ozempic and Wegovy around the time of procedures. It matters because these drugs slow stomach emptying, so food can remain in the stomach even after standard fasting, raising aspiration risk during sedation.Source
Persistence and adherence
In a Prime Therapeutics claims study of Wegovy and Zepbound users without diabetes, persistence meant staying on the drug for a year without a fill gap over 60 days, and adherence meant filling prescriptions on at least 80% of days. Only about 1 in 3 people who started in 2021 stayed on treatment a full year, a rate that nearly doubled by early 2024.Source
Personal importation
Under FDA rules, personal importation covers bringing a medication like Ozempic or Wegovy into the U.S. in your baggage or by mail for your own use, not for resale. It is generally illegal because foreign-bought drugs are often not FDA-approved, though the FDA may allow a three-month supply for a serious condition with no available domestic treatment.Source
Pharmacovigilance
Under FDA rules in 21 CFR 314.80, drug makers like Novo Nordisk, which sells the semaglutide products Ozempic and Wegovy, must have written procedures to watch for, evaluate, and report postmarketing adverse drug experiences to the agency. In practice, serious and unexpected side effects must reach the FDA within 15 calendar days, which is how safety problems get caught after a GLP-1 drug is in wide use.Source
Phase 3 trial
A Phase 3 trial is the large, late-stage human study that tests a drug such as semaglutide against a placebo or standard treatment in many participants, as recorded on ClinicalTrials.gov, for example the STEP 1 trial of Ozempic for weight management. For a US patient, positive Phase 3 results are typically what the FDA reviews before deciding whether to approve the drug for a specific use.Source
Placebo
In the FDA clinical trials that led to Ozempic's approval, a placebo is an inactive injection given to some participants so researchers can compare their results with those of people receiving actual semaglutide. This comparison is what showed whether Ozempic truly improves blood sugar, weight, and heart and kidney outcomes rather than patients improving by chance or expectation.Source
Preconception washout
A preconception washout, for Zepbound (tirzepatide), means stopping the drug before trying to become pregnant, since the FDA label states Zepbound may cause fetal harm and should be discontinued when pregnancy is recognized. In practice, a US patient planning pregnancy should talk with her prescriber about timing, because the label does not specify how long to wait after the last weekly injection.Source
Preemption
In MDL 3163, the NAION vision-loss litigation over Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound, preemption is a potential defense in which Novo Nordisk and Eli Lilly would argue that federal FDA oversight of drug labels overrides state-law failure-to-warn claims. The FDA's decision not to add a NAION warning as of September 2026 is central to whether those claims survive.Source
Preprint
The source text (the ClinicalTrials.gov glossary attached to the STEP 1 registry record) does not define or mention "preprint," so no definition can be written from it.Source
Prescribing information vs marketing claim
The FDA-approved Wegovy Prescribing Information describes what was actually studied, such as a placebo-controlled trial of the 25 mg oral tablet, while marketing claims are promotional statements made by the maker, Novo Nordisk. In a 2026 untitled letter, FDA's Office of Prescription Drug Promotion found a Wegovy TV ad misleading because it suggested the pill was superior to other GLP-1 weight-loss treatments, a claim not supported by the prescribing information.Source
Preserved vs preservative-free formulation
In Zepbound (tirzepatide), single-dose pens and vials hold one preservative-free dose, while multi-dose vials and the single-patient-use KwikPen hold four doses for one person only. For a US patient, this affects how a product is used and stored, since a KwikPen must never be shared between patients even with a new needle.Source
Primary endpoint
In trials of GLP-1 medications such as semaglutide (studied in the STEP 1 trial registered on ClinicalTrials.gov), the primary endpoint is the main result the study was designed to measure, such as the percentage of body weight participants lost. When a patient reads that a drug met its primary endpoint, it means the trial succeeded on the key question regulators and researchers cared about most.Source
Prior authorization
The 2025 KFF Employer Health Benefits Survey source text does not mention prior authorization or describe how it applies to GLP-1 medications, so no definition can be written from this source.Source
Q
Quantity limit
A quantity limit, also called a supply limit or QL, is a cap UnitedHealthcare's pharmacy benefit sets on the maximum amount of a drug covered within a copay period or set timeframe. For a patient filling a GLP-1 prescription, this means insurance may only pay for a set number of pens or tablets per month, with anything beyond that requiring an override or approval.Source
R
Randomized controlled trial
A randomized controlled trial, such as the STEP 1 trial that tested semaglutide (Wegovy) for weight management, assigns participants to treatment arms by chance, with some receiving the study drug and others receiving a placebo or comparator. For a US patient, this design is considered the strongest way to show whether a GLP-1 medication actually works, because chance assignment reduces bias in the results.Source
Randomized withdrawal trial
A randomized withdrawal trial, like the SURMOUNT-4 study of tirzepatide (Mounjaro and Zepbound), randomly assigns some participants to stop or switch from the active drug after an initial treatment period, while others keep taking it. This design shows whether weight loss holds up when a GLP-1 medication is discontinued, which helps US patients and doctors understand what to expect if treatment stops.Source
Real-world evidence
Real-world evidence, in the context of GLP-1 medications like semaglutide and tirzepatide, comes from studies such as a Vanderbilt obesity clinic review of 2,306 patients rather than controlled trials like STEP or SURMOUNT. For US patients, it shows how these drugs actually perform outside trials—in that study, people who stayed on therapy for 12 months or more lost a median of 14.4% of body weight, close to trial results.Source
Reauthorization
Under Aetna's Zepbound (tirzepatide) policy 6192-C, reauthorization—called continuation of therapy—requires at least 3 months on a stable maintenance dose plus documented weight loss of at least 5 percent of baseline body weight, or maintenance of that loss. In practice, a patient whose Zepbound coverage is up for renewal must show the drug is working, and approval for continued therapy lasts 12 months.Source
Rebate
The KFF 2025 Employer Health Benefits Survey source text does not contain any information about rebates as they relate to GLP-1 medications or drug pricing, so a definition cannot be written from this source.Source
Refill rule
Under LillyDirect's Zepbound Self Pay Journey Program, patients must buy their refill of Zepbound (tirzepatide) single-dose vials or KwikPens within 45 days of receiving their previous shipment to keep the $449 monthly purchase offer. Waiting longer than 45 days means the discounted price no longer applies, so a US patient who pauses treatment may pay the regular price, up to $699 for a one-month supply.Source
Research-use-only peptide
A gray market peptide in the GLP-1 context refers to active pharmaceutical ingredients sold for use in non-FDA-approved compounded drugs that companies market as alternatives to FDA-approved medications like Ozempic and Wegovy. The FDA has announced it intends to restrict these products because it cannot verify their quality, safety, or efficacy, and sellers may face seizure, injunction, or other legal action.Source
Rule 702 hearing
In MDL-3163, the federal vision-loss litigation over Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound, a Rule 702 (or Daubert) hearing is where Judge Karen S. Marston would decide whether each side's scientific experts may testify at trial. For a US patient suing over NAION-related vision loss, the outcome of this hearing can determine whether studies like the Harvard JAMA Ophthalmology findings are allowed as evidence in their case.Source
Rybelsus
The tablet form of semaglutide, a GLP-1 receptor agonist the FDA approved for adults with type 2 diabetes to improve blood sugar control and to reduce the risk of major cardiovascular events in those at high risk. Unlike injected Ozempic, it is swallowed whole once daily on an empty stomach with water, and patients must wait at least 30 minutes before eating or taking other oral medications.Source
S
Sarcopenia
A progressive loss of muscle mass and strength that affected 27.7% of participants in a 24-month study of older adults with type 2 diabetes taking semaglutide (Ozempic, Wegovy, Rybelsus), where the drug was linked to faster muscle loss, especially at higher doses. For US patients 65 and older, this means muscle health may need monitoring while on the drug, with nutrition and exercise possibly helping offset the decline.Source
Savings card tier
Within Lilly's Zepbound savings card program, a tier is the fixed copay level a patient lands in based on whether their commercial insurance covers Zepbound, such as $25 with coverage or $299–$499 without it. In practice, the tier determines a US patient's out-of-pocket cost, with savings capped monthly and annually and the card expiring 12/31/2026.Source
Section 337 / ITC exclusion order
Section 337 of the Tariff Act of 1930 lets Eli Lilly, maker of Mounjaro and Zepbound, ask the U.S. International Trade Commission to block imports that infringe its trademark, and the ITC issued a general exclusion order covering tirzepatide products. For US patients, this keeps unauthorized tirzepatide products from entering the country, affecting availability of non-FDA-approved versions sold online.Source
Self-funded plan
A self-funded plan, also called a self-insured plan, is an employer health benefit plan covered under ERISA in which the employer pays claims directly rather than buying insurance, and it must follow the Department of Labor's claims procedure rules under 29 CFR 2560.503-1. For a patient seeking GLP-1 medications like Ozempic or Wegovy, a coverage denial must come with the plan's appeal procedures.Source
Self-pay / cash price
Paying for a GLP-1 medicine out of pocket instead of using insurance, an option Novo Nordisk offers through NovoCare Pharmacy for Wegovy and Ozempic, with self-pay prices starting at $149 a month for the pills and $199 for the pens. For US patients, this route requires no insurance but still requires a prescription, and prices vary by dose.Source
Self-pay price
The self-pay price is what a patient pays for Zepbound (tirzepatide) directly through LillyDirect without insurance, such as the Zepbound Self Pay Journey Program's flat $449 for a one-month supply of the 7.5 mg to 15 mg doses. For US patients without coverage, this route offers a predictable cost, though regular prices range from $299 to $699 by dose and Lilly can change the offer at any time.Source
Semaglutide
Developed by Novo Nordisk, semaglutide is a GLP-1 receptor agonist sold in the US as Ozempic, Wegovy, and Rybelsus, first approved by the FDA as a weekly injection for type 2 diabetes in December 2017. For American patients, it comes as a once-weekly shot or a once-daily tablet, and in 2021 the FDA also approved it for chronic weight management in adults with obesity or overweight plus a weight-related condition.Source
Semaglutide sodium / semaglutide acetate
These salt forms are different active ingredients from the semaglutide in FDA-approved drugs like Ozempic, Wegovy and Rybelsus, and the FDA knows of no lawful basis for their use in compounding. For a US patient, that means a compounded product labeled semaglutide sodium or acetate may not work the same way as the approved drug.Source
Sharps container
An FDA-cleared sharps disposal container is a rigid plastic bin that the FDA has evaluated for safety and recommends for immediately discarding used needles, such as those from injectable GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Patients can buy these containers at pharmacies, medical supply companies, or online, and they should be disposed of through community guidelines once they are about three-quarters full.Source
Sharps disposal
The FDA recommends that people injecting GLP-1 drugs like Ozempic, Wegovy, Mounjaro, or Zepbound place used needles in a sharps disposal container right away and get rid of the full container through local programs such as drop boxes, mail-back services, or hazardous waste sites. This lowers the risk of needle sticks and cuts, and since rules vary by community, patients should check with their local trash service or health department.Source
Signal
A signal, in this case, is the warning WHO issued in June 2025 about a possible link between semaglutide medicines (Ozempic, Rybelsus, and Wegovy) and NAION, a rare eye condition that causes sudden vision loss. For US patients, it means regulators worldwide are tracking this risk, so any sudden loss of vision while on these drugs should be reported to a doctor right away.Source
Single-dose pen
Wegovy (semaglutide) injection comes in a prefilled, single-dose pen that delivers one fixed amount of medicine, available in strengths of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, or 7.2 mg (Wegovy HD). Because each pen holds only one weekly dose, a patient uses a fresh pen for every injection and throws it away afterward, which removes the need to measure or mix the medication.Source
Single-dose vial
A packaging option for Zepbound (tirzepatide) sold through LillyDirect, where each vial holds one weekly dose of the injectable weight-loss medicine in strengths from 2.5 mg to 15 mg. Patients who choose this self-pay option must buy a separate needle and syringe for each injection, since the vial itself does not include them.Source
Small molecule
In the context of GLP-1 medications, a small molecule refers to a medicine like Foundayo (orforglipron), which comes as a tablet taken by mouth once daily rather than as an injection. For US patients, this means a GLP-1 option that can be swallowed whole with or without food, without refrigeration or needles.Source
SNAC
Salcaprozate sodium (SNAC) is the absorption-enhancing ingredient that lets semaglutide be taken as a tablet, which is why Rybelsus and Ozempic tablets exist as oral forms of a drug otherwise given by injection. Because this absorption process is delicate, patients must take the tablet on an empty stomach with water only and wait at least 30 minutes before eating, drinking, or taking other oral medications.Source
sNDA / supplement
A supplemental new drug application (sNDA) is a request a drug maker files with the FDA to change an already-approved product, such as the December 2025 filing by Novo Nordisk to update the Ozempic (semaglutide) pen instructions. For US patients, an approved supplement can mean updated labeling or instructions, like the change confirming the pen works with needles from makers other than Novo Nordisk.Source
Starting dose
For Rybelsus and Ozempic tablets, the FDA-approved starting dose is 3 mg of semaglutide taken by mouth once daily for the first 30 days, a level that on its own is not effective for blood sugar control. In practice, a patient begins at this low dose so the body can adjust before stepping up to 7 mg, which helps limit stomach-related side effects.Source
Steady state
With Ozempic (semaglutide), steady state is the point at which weekly injections build up so the drug level stays roughly even between doses, which the FDA prescribing information ties to staying on each dose step for at least 4 weeks before increasing it. In practice, full effects and side effects like nausea become consistent only after several weeks of regular once-weekly dosing.Source
Step therapy
Under step therapy, sometimes called "fail first," an insurer requires a patient to try and not do well on other treatments before it will cover a newer, costlier drug such as Wegovy or Zepbound. For a US patient seeking a GLP-1 medication, this can mean extra months of trying other options first, since employers and plans use such rules to manage the high cost of these drugs.Source
Step therapy override
A step therapy override, also called a step therapy exception, is a request a patient or doctor makes to an insurer to skip required trial of cheaper drugs first and cover a GLP-1 medication like Ozempic or Wegovy directly. Many states have laws protecting consumers in this process, though they may not apply to self-funded plans, so a US patient may need to check state rules before appealing.Source
Step-down dosing
Step-down dosing, tested in the SURMOUNT-MAINTAIN trial published in The Lancet, is the practice of lowering a GLP-1 medication dose after a person reaches a weight or treatment goal rather than stopping the drug entirely. For a US patient, this approach may help hold onto results while reducing cost or side effects, though the trial's findings show outcomes depend on how the dose is lowered.Source
Subcutaneous injection
Ozempic (semaglutide) is delivered as a shot given into the fatty layer just under the skin, in the abdomen, thigh, or upper arm, once a week. For a US patient, this means self-injecting with a prefilled pen at home, using a different spot each week when injecting in the same body area.Source
SURMOUNT
Eli Lilly uses the SURMOUNT name for its series of clinical trials studying tirzepatide (sold as Mounjaro and Zepbound), with each trial getting a suffix, such as SURMOUNT-MMO, registered on ClinicalTrials.gov under NCT05556512. For a US patient, seeing the SURMOUNT name signals that the results come from the company's own research program on tirzepatide, which can help when comparing it with trials for other GLP-1 medications.Source
SURPASS
SURPASS names the series of clinical trials, including SURPASS-2 published in the New England Journal of Medicine, that tested Eli Lilly's tirzepatide (sold as Mounjaro and Zepbound) against other treatments in adults with type 2 diabetes. SURPASS-2 in particular compared once-weekly tirzepatide with once-weekly semaglutide, giving US patients head-to-head evidence between two widely prescribed injectable GLP-1 options.Source
Sympathomimetic amine
Phentermine, an amphetamine derivative prescribed for short-term obesity treatment, belongs to this drug class, which is separate from GLP-1 medications like Ozempic and Wegovy. A patient with a known allergy or unusual reaction to these compounds should not take phentermine, so it matters for anyone weighing it against GLP-1 options.Source
T
Tachyphylaxis
The Mounjaro (tirzepatide) prescribing information from the FDA does not discuss tachyphylaxis, so the label offers no guidance on whether the drug's effects fade with continued use. Patients who feel their response to Mounjaro is weakening over time should raise the question with their prescriber rather than adjusting the dose on their own.Source
Tainted supplement
A tainted supplement, also called a hidden drug ingredient, is a weight loss product that secretly contains an undeclared pharmaceutical, such as sibutramine, phenolphthalein, or fluoxetine, added by unethical manufacturers to boost its effects. For a US patient, this matters because such products carry serious risks like heart problems, depression, or insomnia, and the FDA prohibits some of these compounds entirely.Source
Target trial emulation
A research method used in the BMJ 2026 study of GLP-1 drugs and hair loss, where researchers design an ideal randomized trial on paper, then imitate it with real-world electronic health records from Penn Medicine. For US patients, this means the study's findings—such as a higher hair loss risk with GLP-1 receptor agonists versus SGLT-2 or DPP-4 inhibitors—come from actual patient data rather than a formal clinical trial.Source
Telehealth
Online companies that sell compounded GLP-1 drugs like semaglutide have drawn FDA warning letters for promoting these products with false or misleading claims. For a US patient, this means a telehealth website may overstate what its compounded drug offers, since compounded versions are not FDA-reviewed for safety, effectiveness, or quality before they are sold.Source
Tentative approval
When the FDA reviews a generic GLP-1 application, such as one referencing Victoza (liraglutide) or Byetta (exenatide), a tentative approval signals the agency found the product acceptable but held back full approval because of existing rights on the brand-name drug. For a US patient, this means a cheaper generic GLP-1 option has cleared the FDA's safety and effectiveness review but cannot be sold until those rights expire.Source
Tiering exception
A tiering exception is a Medicare Part D coverage determination request that asks a plan sponsor to cover a non-preferred drug, such as Ozempic or Wegovy, at the lower cost-sharing of a preferred formulary tier. The prescriber must submit a supporting statement saying the preferred drugs would be less effective or cause adverse effects, and the plan must decide within 72 hours for standard requests.Source
Tirzepatide
Tirzepatide, the active ingredient in Mounjaro, is a GIP and GLP-1 receptor agonist that the FDA approved in 2022 to improve blood sugar control in people with type 2 diabetes, given as a once-weekly injection under the skin. For US patients, it works alongside diet and exercise, with doses starting at 2.5 mg and rising gradually to a maximum of 15 mg weekly in adults.Source
Titration
Ozempic's FDA prescribing information calls for starting at 0.25 mg once weekly for 4 weeks, then stepping up to 0.5 mg, 1 mg, or 2 mg, with each increase spaced at least 4 weeks apart. This gradual dose escalation lowers the chance of gastrointestinal side effects like nausea, vomiting, and diarrhea, so patients should expect their weekly dose to rise slowly rather than all at once.Source
Topline results
On the ClinicalTrials.gov record for the STEP 1 trial of semaglutide (Wegovy), topline results are the summary outcome information a sponsor submits to the registry, such as the main weight-loss findings, before full details appear in a journal. For a US patient, these posted numbers offer an early look at how the drug performed, though they are brief summaries rather than the complete analyzed data.Source
Triple agonist
A drug that activates three hormone receptors at once — GIP, GLP-1, and glucagon — rather than just one; Eli Lilly's investigational retatrutide is the first triple agonist being tested for obesity. In the Phase 3 TRIUMPH-1 trial, it produced weight loss comparable to bariatric surgery, but it remains available only to clinical trial participants in the US.Source
TrumpRx
TrumpRx.gov is a website launched by President Trump in February 2026 that offers large discounts on popular high-priced medicines, including Ozempic, Wegovy, and Zepbound, at most-favored-nation prices from manufacturers like Novo Nordisk and Eli Lilly. For US patients with valid prescriptions, it can mean paying as little as $199 a month for Ozempic or $299 for Zepbound through printable or phone-based coupons.Source
Type 2 diabetes
Adults with type 2 diabetes mellitus are the population the FDA approved Ozempic (semaglutide) for, alongside diet and exercise, to improve glycemic control and to reduce risks tied to cardiovascular or chronic kidney disease. For a US patient, this diagnosis is the key factor in whether Ozempic is an approved treatment option and in how insurance coverage for the drug is typically handled.Source
U
U-100 syringe
A U-100 syringe, also called an insulin syringe, is a 1-milliliter measuring device that some compounders and telemedicine providers have told patients to use for drawing small doses of compounded semaglutide from multiple-dose vials. FDA reports show that confusion over its "unit" markings has led patients to inject up to 10 times the intended dose, so patients should confirm the right syringe and measurement method with their provider.Source
Unit (syringe unit)
On compounded injectable labels, FDA case reports showed that strength per milliliter, such as 10 mg/mL on a syringe, was sometimes printed in large font and mistaken for the total amount of drug in the syringe. For a patient, misreading that number can lead to an overdose, which is why FDA recommends labels show the total amount per syringe first, with the per-milliliter strength in parentheses.Source
Untitled letter
An untitled letter is a warning the FDA's Office of Prescription Drug Promotion sends when it finds a drug ad false or misleading, as in the February 2026 letter to Novo Nordisk over a Wegovy pill TV ad. For a US patient, it means claims like "live lighter" lacked evidence, and the company must respond within 15 working days and stop the misleading promotion.Source
W
WAC
WAC, or wholesale acquisition cost, is the list price a manufacturer sets for a GLP-1 drug before any discounts, such as the $1,349 monthly list price for Wegovy or $936 for Ozempic and Rybelsus in the U.S. In practice, patients and insurers often pay less than this amount because of rebates and coupons, though U.S. list prices still run several times higher than in peer nations.Source
Warning letter
In September 2025, the FDA's Center for Drug Evaluation and Research sent a warning letter to Hims & Hers Health, Inc. saying its website's claims about compounded semaglutide, like "same active ingredient as Ozempic and Wegovy," were false or misleading because compounded drugs are not FDA-approved. For patients, it signals that marketing compounded GLP-1s as equivalent to approved drugs can trigger FDA enforcement.Source
Warnings and precautions
The FDA-approved Ozempic (semaglutide) label lists warnings and precautions including acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin, severe gastrointestinal reactions, hypersensitivity, gallbladder disease, and pulmonary aspiration during anesthesia. In practice, this section tells patients and doctors which serious risks to watch for, such as telling surgeons about planned procedures before anesthesia and not sharing an Ozempic pen with anyone else.Source
Wegovy
Novo Nordisk's FDA-approved brand of semaglutide, a GLP-1 receptor agonist offered as a once-weekly injection or a daily tablet, first approved in the U.S. in 2017. It is prescribed with diet and exercise for long-term weight management in adults and children 12 and older, to lower cardiovascular risk in adults with heart disease and obesity or overweight, and to treat noncirrhotic MASH with moderate to advanced liver fibrosis.Source
Wegovy HD
The highest-strength version of the Wegovy (semaglutide) injection pen, delivering a 7.2 mg once-weekly dose, is listed in the FDA prescribing information alongside pens of 0.25 mg through 2.4 mg. For US patients, it represents a maintenance dose option above the usual 2.4 mg, reached only through the step-up dosing schedule a prescriber directs.Source
Wegovy tablets
Wegovy tablets are an oral form of semaglutide, a GLP-1 receptor agonist from Novo Nordisk that the FDA approved for weight reduction and cardiovascular risk reduction in adults with obesity or overweight. Patients take one tablet daily on an empty stomach with water, starting at 1.5 mg and titrating up to a 25 mg maintenance dose, instead of receiving weekly injections.Source
Weight regain
In the Gasoyan et al. study of adults taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for obesity, patients who stopped treatment early lost far less weight at one year—about 3.6% versus 11.9% for those who stayed on the drug. For a US patient, this means stopping the medication or dropping to a lower dose can undo much of the expected weight loss.Source
Weight-loss plateau
In the SURMOUNT-1 and SURMOUNT-4 trials of tirzepatide (Mounjaro and Zepbound), a weight plateau was defined as a weight change under 5% over a 12-week interval and every interval after that. Most participants reached this point by week 72, so a stall in results is a normal part of treatment rather than a sign the drug stopped working.Source
Y
YMYL
The source text, Google's November 2024 site reputation abuse policy update, does not mention YMYL or 'Your Money or Your Life' anywhere, so this term cannot be defined from it. A definition based only on this source would be fabricated, and readers looking for how Google treats health and finance content like GLP-1 drug information would need a different source.Source
Z
Zepbound
Tirzepatide, sold under the brand name Zepbound, is a once-weekly FDA-approved injection that acts on both GIP and GLP-1 receptors to reduce excess body weight and treat moderate to severe obstructive sleep apnea in adults with obesity. For a US patient, dosing starts at 2.5 mg weekly and can rise to a maximum of 15 mg, and the pen should never be shared with another person.Source
